Amalia Ysabelle
Sep 21, 2017
Featured

Flaws in the IPR process give rise to some very inventive patent solutions

Before making a mad dash to follow Allergan plc's lead in handing off key patents to an Indian tribe to avoid inter partes reviews (IPRs), other drug and med-tech companies may want to watch from the sidelines to see how the U.S. Supreme Court rules in a case that could doom the entire IPR process

http://bit.ly/2xflIJ6